BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 9,134 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 2.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 429,077 shares of the specialty pharmaceutical company's stock after selling 9,134 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.69% of Jazz Pharmaceuticals worth $47,804,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JAZZ. Versant Capital Management Inc raised its stake in Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock valued at $29,000 after acquiring an additional 269 shares during the period. Itau Unibanco Holding S.A. acquired a new position in Jazz Pharmaceuticals in the 2nd quarter valued at about $29,000. EverSource Wealth Advisors LLC lifted its position in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock worth $30,000 after acquiring an additional 97 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock valued at $31,000 after purchasing an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP bought a new position in shares of Jazz Pharmaceuticals during the second quarter worth approximately $33,000. 89.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on JAZZ shares. Royal Bank of Canada increased their price objective on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 23rd. Piper Sandler restated an "overweight" rating and set a $163.00 target price (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research report on Thursday. TD Cowen cut their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a research note on Thursday, November 7th. Needham & Company LLC reaffirmed a "buy" rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $175.33.

Jazz Pharmaceuticals Trading Up 1.3 %

NASDAQ JAZZ traded up $1.57 during mid-day trading on Friday, reaching $126.67. 903,134 shares of the stock were exchanged, compared to its average volume of 679,455. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $7.66 billion, a P/E ratio of 17.62, a P/E/G ratio of 0.98 and a beta of 0.57. The stock has a 50 day simple moving average of $113.29 and a 200-day simple moving average of $110.62. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $134.17.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the company's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now owns 428,976 shares in the company, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,110 shares of company stock valued at $720,160. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.